Literature DB >> 26105002

Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms.

Denis V Abramochkin1, Vladislav S Kuzmin, Leonid V Rosenshtraukh.   

Abstract

A new class III antiarrhythmic drug niferidil has been recently introduced as a highly effective therapy cure for cases of persistent atrial fibrillation, but ionic mechanisms of its action are still unknown. Effects of niferidil on action potential (AP) waveform and major ionic currents were studied in mouse ventricular myocardium. APs were recorded with glass microelectrodes in multicellular preparations of right ventricular wall. Whole-cell patch-clamp technique was used to measure K(+), Ca(2+), and Na(+) currents in isolated mouse ventricular myocytes. While 10(-7) M niferidil failed to alter the AP configuration, 10(-6) M tended to prolong APs (by 12.05 ± 1.8% at 50% of repolarization) and 10(-5) M induced significant slowing of repolarization (32.1 ± 4.9% at 50% of repolarization). Among the potassium currents responsible for AP repolarization phase, IK1 was found to be almost insensitive to niferidil. Ito demonstrated low sensitivity to niferidil with IC50 = 2.03 × 10(-4) M. IKur, which was previously hypothesized to be the main target of the drug, was more sensitive with IC50 = 6 × 10(-5) M. However, sustained delayed rectifier potassium current Iss was inhibited with even lower IC50 = 2.8 × 10(-5) M. Therefore, suppression of Iss and, second, IKur by niferidil seems to underlie the AP prolongation in mouse ventricular tissue. Niferidil also produced a modest decrease in ICaL peak amplitude (IC50≈10(-4) M), but failed to alter INa significantly. Niferidil prolongs APs in mouse ventricular myocardium mainly by inhibiting Iss and IKur K(+) currents, but not exclusively IKur, as was proposed earlier. Further investigations are required to reveal the mechanisms of niferidil action in human myocardium, where IKr is strongly expressed instead of Iss.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26105002     DOI: 10.1007/s00210-015-1146-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

Review 1.  Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity.

Authors:  S Nattel; L Yue; Z Wang
Journal:  Cell Physiol Biochem       Date:  1999

2.  [Ionic mechanisms of cardiotropic action of a new class III antiarrhythmic drug RG-2].

Authors:  A V Reznik; V V Fedorov; Iu M Kokoz; A F Korystova; L V Rozenshtraukh; S P Golitsyn; M Ia Ruda; E I Chazov
Journal:  Kardiologiia       Date:  2003       Impact factor: 0.395

Review 3.  Inwardly rectifying potassium channels: their structure, function, and physiological roles.

Authors:  Hiroshi Hibino; Atsushi Inanobe; Kazuharu Furutani; Shingo Murakami; Ian Findlay; Yoshihisa Kurachi
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

Review 4.  Vernakalant: A novel agent for the termination of atrial fibrillation.

Authors:  Miki Finnin
Journal:  Am J Health Syst Pharm       Date:  2010-07-15       Impact factor: 2.637

5.  Characterization of nifedipine block of the human heart delayed rectifier, hKv1.5.

Authors:  X Zhang; J W Anderson; D Fedida
Journal:  J Pharmacol Exp Ther       Date:  1997-06       Impact factor: 4.030

6.  Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium".

Authors:  G Isenberg; U Klockner
Journal:  Pflugers Arch       Date:  1982-10       Impact factor: 3.657

7.  Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.

Authors:  Johann Reisinger; Edmund Gatterer; Wolfgang Lang; Thetis Vanicek; Geza Eisserer; Theresia Bachleitner; Christopher Niemeth; Friedrich Aicher; Wilhelm Grander; Georg Heinze; Peter Kühn; Peter Siostrzonek
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

8.  Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.

Authors:  Christopher P Regan; Laszlo Kiss; Gary L Stump; Charles J McIntyre; Douglas C Beshore; Nigel J Liverton; Christopher J Dinsmore; Joseph J Lynch
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

9.  Different mechanisms of the inhibition of the transient outward current in rat ventricular myocytes.

Authors:  U Jahnel; P Klemm; H Nawrath
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

10.  Four kinetically distinct depolarization-activated K+ currents in adult mouse ventricular myocytes.

Authors:  H Xu; W Guo; J M Nerbonne
Journal:  J Gen Physiol       Date:  1999-05       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.